Thomas R. Kosten, MD

Reasons for Maintaining the Classification of Esmethadone as an Investigational Uncompetitive NMDAR Antagonist Rapid Antidepressant: Reply to Ferré and Michaelides

September 8, 2025

The authors reply to Ferré and Michaelides’ letter commenting on their recent study of long-term esmethadone treatment in MDD.

Sara De Martin, Stefano Comai, Andrea Mattarei, et al

Original Research

Long-Term Safety and Efficacy of Esmethadone in MDD

February 17, 2025

A durable improvement in MDD symptoms for up to 1 year was observed with esmethadone with high rates of response and remission.

Maurizio Fava, Luca Pani, Sara De Martin, et al

Original Research

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

June 17, 2024

Although this trial of esmethadone did not meet its primary outcome, some secondary and post hoc outcomes were promising.

Maurizio Fava, Luca Pani, Sara De Martin, et al

Original Research

Suicide Risk in a National VA Sample

June 6, 2022

Predicting suicide is difficult, as suicidal behavior is not linked solely to any single behavior or psychiatric diagnosis. This study compared risk of suicidal behavior among a transdiagnostic sample...

Alan C. Swann, David P. Graham, Anna V. Wilkinson, et al

Original Research

Extensive White Matter Abnormalities and Clinical Symptoms in Drug-Naive Patients With First-Episode Schizophrenia: A Voxel-Based Diffusion Tensor Imaging Study

February 24, 2016

Jair C. Soares, Thomas R. Kosten, Xiang Yang Zhang, et al

Original Research

The Type 2 Diabetes Mellitus Susceptibility Gene IGF2BP2 Is Associated With Schizophrenia in a Han Chinese Population

April 15, 2013

Thomas R. Kosten, Xiang Yang Zhang, Li Hui, et al

Article

Gender Differences in Never-Medicated First-Episode Schizophrenia and Medicated Chronic Schizophrenia Patients

July 15, 2012

Fu De Yang, Thomas R. Kosten, Xiang Yang Zhang, et al

Letter to the Editor

Aripiprazole Treatment of Risperidone-Induced Hyperprolactinemia

July 21, 2009

Jing Xu Chen, Yun Ai Su, Shao Li Wang, et al

Original Research

Disrupted Antioxidant Enzyme Activity and Elevated Lipid Peroxidation Products in Schizophrenic Patients With Tardive Dyskinesia

May 15, 2007

Thomas R. Kosten, Xiang Yang Zhang, Yun Long Tan, et al

Reasons for Maintaining the Classification of Esmethadone as an Investigational Uncompetitive NMDAR Antagonist Rapid Antidepressant: Reply to Ferré and Michaelides

Long-Term Safety and Efficacy of Esmethadone in MDD

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

Suicide Risk in a National VA Sample

Extensive White Matter Abnormalities and Clinical Symptoms in Drug-Naive Patients With First-Episode Schizophrenia: A Voxel-Based Diffusion Tensor Imaging Study

The Type 2 Diabetes Mellitus Susceptibility Gene IGF2BP2 Is Associated With Schizophrenia in a Han Chinese Population

Gender Differences in Never-Medicated First-Episode Schizophrenia and Medicated Chronic Schizophrenia Patients

Aripiprazole Treatment of Risperidone-Induced Hyperprolactinemia

Disrupted Antioxidant Enzyme Activity and Elevated Lipid Peroxidation Products in Schizophrenic Patients With Tardive Dyskinesia

ELSEWHERE:

FOLLOW US:

Thomas R. Kosten, MD

Reasons for Maintaining the Classification of Esmethadone as an Investigational Uncompetitive NMDAR Antagonist Rapid Antidepressant: Reply to Ferré and Michaelides

Long-Term Safety and Efficacy of Esmethadone in MDD

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

Suicide Risk in a National VA Sample

Extensive White Matter Abnormalities and Clinical Symptoms in Drug-Naive Patients With First-Episode Schizophrenia: A Voxel-Based Diffusion Tensor Imaging Study

The Type 2 Diabetes Mellitus Susceptibility Gene IGF2BP2 Is Associated With Schizophrenia in a Han Chinese Population

Gender Differences in Never-Medicated First-Episode Schizophrenia and Medicated Chronic Schizophrenia Patients

Aripiprazole Treatment of Risperidone-Induced Hyperprolactinemia

Disrupted Antioxidant Enzyme Activity and Elevated Lipid Peroxidation Products in Schizophrenic Patients With Tardive Dyskinesia

Watch the New PsychCase360

Subscribe to readmore articles

Subscribe to read
more articles